Navigation Links
New findings may improve treatment of inherited breast cancer
Date:10/9/2008

They went on to show that the compound resveratrol strongly inhibited BRCA1-mutant tumor growth in cultured cells and animal models. Resveratrol is an important constituent of traditional Japanese and Chinese medicine that has recently been shown to inhibit some types of cancer by inducing apoptosis with very little associated toxicity. In the current paper, resveratrol enhanced SIRT1 activity, this leading to reduced Survivin expression and subsequent apoptosis of BRCA1 deficient cancer cells.

These findings identify SIRT1 and Survivin as downstream mediators of BRCA1-regulated tumor suppression and identify resveratrol as a potent inhibitor of BRCA1-mutant cancer cells. "Resveratrol may serve as an excellent compound for targeted therapy for BRCA1 associated breast cancers," says Dr. Deng.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Curemark CEO Presents Autism Findings at Prestigious Neurobiology Conference at Oxford
2. Endoscopic ultrasound highly accurate in evaluating ambiguous radiographic findings of the pancreas
3. Positive Findings Published on Emergent Technology for Treating Chronic Pain
4. New Survey Findings Reveal Emotional and Physical Toll of Rheumatoid Arthritis and the Advancement of Treatment Through Generations
5. Findings on bladder-brain link may point to better treatments for problems in sleep, attention
6. New Survey Findings Reveal Emotional and Physical Toll of Rheumatoid Arthritis and the Advancement of Treatment through "Generations"
7. The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation
8. Senesco Expands on Preclinical Multiple Myeloma Findings
9. NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting
10. Dartmouth-Hitchcock Medical Center Evaluation Findings Demonstrate Masimo Patient SafetyNet(TM) Delivers Improvements in Clinical Outcomes and Patient Safety on General Care Floors
11. Stop Obesity Alliance, Chair Dr. Richard H. Carmona, National Opinion Research Center Reveal Findings of Survey Showing Employer Concern About Health, Financial Costs of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 2ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 3Masimo to Report Second Quarter 2009 Financial Results on August 4 2009 52366 1Masimo to Report Second Quarter 2009 Financial Results on August 4 2009 52366 2Masimo to Report Second Quarter 2009 Financial Results on August 4 2009 52366 3Nexavar in Combination with Chemotherapy Shown to Extend Progression Free Survival in Patients with Advanced Breast Cancer 52362 1Nexavar in Combination with Chemotherapy Shown to Extend Progression Free Survival in Patients with Advanced Breast Cancer 52362 2Nexavar in Combination with Chemotherapy Shown to Extend Progression Free Survival in Patients with Advanced Breast Cancer 52362 3Nexavar in Combination with Chemotherapy Shown to Extend Progression Free Survival in Patients with Advanced Breast Cancer 52362 4Nexavar in Combination with Chemotherapy Shown to Extend Progression Free Survival in Patients with Advanced Breast Cancer 52362 5Nexavar in Combination with Chemotherapy Shown to Extend Progression Free Survival in Patients with Advanced Breast Cancer 52362 6NBTY Acquisition of Julian Graves Unconditionally Cleared 52360 1NBTY Acquisition of Julian Graves Unconditionally Cleared 52360 2NBTY Acquisition of Julian Graves Unconditionally Cleared 52360 3NBTY Acquisition of Julian Graves Unconditionally Cleared 52360 4NBTY Acquisition of Julian Graves Unconditionally Cleared 52360 5